PTC Therapeutics (PTCT) is the lead sponsor of 4 active clinical trials listed on ClinicalTrials.gov[3], including 3 Phase 3[1], 1 Phase 2[2].
Trial NCT05515536[4] evaluates Vatiquinone in Friedreich Ataxia with a target enrollment of 130 participants. Trial NCT06302348[5] evaluates Sepiapterin in Phenylketonuria with a target enrollment of 56 participants. Trial NCT05166161[6] evaluates PTC923 in Phenylketonuria with a target enrollment of 200 participants.
PTCT has 6 Form 4 insider filings recorded at the SEC in the past 30 days[7].